<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525352</url>
  </required_header>
  <id_info>
    <org_study_id>RP-L401-0120</org_study_id>
    <nct_id>NCT04525352</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis</brief_title>
  <official_title>A Phase I Clinical Trial for Gene Therapy in Infantile Malignant Osteopetrosis (IMO) to Evaluate the Safety and Preliminary Efficacy of Autologous CD34+ Enriched Cells Transduced With a LV Vector Encoding the TCIRG1 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rocket Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rocket Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase 1 study is to evaluate the therapeutic safety and&#xD;
      feasibility of the investigational product (IP), RP-L401.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized Phase 1 study to evaluate the preliminary safety and efficacy of&#xD;
      hematopoietic gene therapy consisting of autologous CD34+ enriched hematopoietic cells&#xD;
      transduced with the lentiviral vector (LV) carrying the human TCIRG1 transgene (RP-L401) in&#xD;
      pediatric patients with IMO. Following myeloablative conditioning patients will receive an&#xD;
      infusion of the genetically modified hematopoietic stem and progenitor cells (HSPCs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of safety associated with treatment with RP-L401</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of vector copy number (VCN) after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of the presence of gene-modified blood and bone marrow cells post infusion via blood and bone marrow assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of endocrine and metabolic status after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of normalization of serum calcium levels via a blood assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of blood counts after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of the stabilization or improvement in blood counts as assessed by NCI CTACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of bone abnormalities after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of the qualitative improvement in bone formation via x-ray studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of auditory status after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of the stabilization or improvement in hearing loss via auditory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ophthalmology status after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of optical abnormalities via visual assessments of the eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hepatosplenomegaly after infusion of RP-L401</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of hepatosplenomegaly improvement via abdominal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of head, mouth and gum abnormalities</measure>
    <time_frame>2 years</time_frame>
    <description>Photographic documentation of head, mouth and gums to assess disease stabilization, progression or improvement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Infantile Malignant Osteopetrosis</condition>
  <arm_group>
    <arm_group_label>Experimental - RP-L401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RP-L401</intervention_name>
    <description>CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene</description>
    <arm_group_label>Experimental - RP-L401</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A confirmed diagnosis of IMO with documented TCIRG1 mutation.&#xD;
&#xD;
          2. Age at least 1 month with minimum weight of 4 kg&#xD;
&#xD;
          3. Absence of debilitating hydrocephalus (defined as hydrocephalus at NCI CTCAE v5.0&#xD;
             Grade 3 or higher persisting despite shunt or similar procedural intervention).&#xD;
&#xD;
          4. Lansky Play Scale of at least 60%&#xD;
&#xD;
          5. Preserved hepatic function (AST/ALT ≤3.0 ULN; bilirubin ≤1.5 ULN; to minimize&#xD;
             potential for excessive toxicity from busulfan conditioning)&#xD;
&#xD;
          6. No concomitant medical or other conditions that would represent a contraindication to&#xD;
             autologous hematopoietic stem cell transplant.&#xD;
&#xD;
          7. Absolute neutrophil count of ≥500/mm3 and platelet count of ≥25,000/mm3&#xD;
&#xD;
          8. No prior allogeneic or other hematopoietic stem cell transplant.&#xD;
&#xD;
          9. Availability of a non-autologous rescue (back-up) hematopoietic stem cell donor/source&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Availability of medically-feasible HLA-matched sibling donor for allogeneic HSCT.&#xD;
&#xD;
          2. Any medical or other contraindication for either apheresis or autologous transplant as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          3. Participation in another clinical trial with an investigational drug within 14 days&#xD;
             before the informed consent signature. Participation in observational studies is&#xD;
             allowed.&#xD;
&#xD;
          4. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer&#xD;
             or another carcinoma in situ.&#xD;
&#xD;
          5. Uncontrolled seizure disorder.&#xD;
&#xD;
          6. Renal dysfunction as defined by a glomerular filtration rate &lt;30 mL/min/1.73m2 or&#xD;
             dialysis dependence.&#xD;
&#xD;
          7. Serious infections with persistent bloodstream pathogens at time of trial entry&#xD;
&#xD;
          8. Pulmonary dysfunction as defined by either:&#xD;
&#xD;
               -  Need for supplemental oxygen during the prior 2 weeks (in absence of acute&#xD;
                  infection) or&#xD;
&#xD;
               -  Oxygen saturation (by pulse oximetry) &lt;90% resulting from pulmonary conditions&#xD;
                  (intermittent hypoxia secondary to IMO-related choanal atresia will not be&#xD;
                  considered exclusionary)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B Kohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired bone resorption</keyword>
  <keyword>Deficient osteoclast development</keyword>
  <keyword>Autosomal Recessive Disorder</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>Bone marrow failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

